Abstract |
Biweekly THP-COPBLM including pirarubicin (THP), which is thought to be less toxic than doxorubicin, was used to treat non-Hodgkin's lymphoma (NHL) and the remission rate and adverse events were studied in 42 patients younger than 69 years. Complete remission (CR) was achieved in 37 patients (88.1%) and partial remission in five (11.9%). Classified by international prognostic index, CR was achieved in 16 out of 17 low-intermediate-risk patients, 14 out of 16 high-intermediate-risk patients and seven out of nine high-risk patients. The 3-year survival rate was 72.1% and the 3-year event-free survival rate was 58%. Grade 3 or higher adverse events included granulocytopenia in 39 patients (92.9%) and thrombocytopenia in seven (16.7%). The biweekly THP-COPBLM regimen appears useful for the treatment of aggressive intermediate- and high-grade NHL, and G-CSF made it possible to shorten the interval between courses of chemotherapy. Further studies regarding adverse events on organs, other than on bone marrow are required to improve the long-term results of combination therapy on NHL.
|
Authors | N Niitsu, M Umeda |
Journal | Leukemia
(Leukemia)
Vol. 12
Issue 9
Pg. 1457-60
(Sep 1998)
ISSN: 0887-6924 [Print] England |
PMID | 9737696
(Publication Type: Journal Article)
|
Chemical References |
- Bleomycin
- Granulocyte Colony-Stimulating Factor
- Procarbazine
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects, analogs & derivatives)
- Drug Administration Schedule
- Female
- Granulocyte Colony-Stimulating Factor
(administration & dosage, adverse effects)
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Prednisone
(administration & dosage, adverse effects)
- Procarbazine
(administration & dosage, adverse effects)
- Survival Analysis
- Vincristine
(administration & dosage, adverse effects)
|